Cinnarizine

Active ingredient description

Cinnarizine has been shown to be a non-competitive antagonist of the smooth muscle contractions caused by various vasoactive agents including histamine. Cinnarizine also acts on vascular smooth muscle by selectively inhibiting the calcium influx into depolarised cells, thereby reducing the availability of free Ca2+ ions for the induction and maintenance of contraction.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
Cinnarizine
N Nervous system → N07 Other nervous system drugs → N07C Antivertigo preparations → N07CA Antivertigo preparations
Discover more medicines within N07CA02

Medicines

Cinnarizine is the active ingredient of these drugs:

Drug
Countries

Hong Kong

Hong Kong

Hong Kong Singapore

Hong Kong

Hong Kong

Cyprus Singapore

Hong Kong

Brazil

Hong Kong

Brazil Cyprus Ireland Lithuania Singapore

Hong Kong

Hong Kong

Cinnarizine is also found within below combination drugs:

ARLEVERT , AZALONUM , CINNAGO , CLINADIL , PHEZAM , PRIMATOUR , TRAVELLER

Product monographs

Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
Summary of product characteristics (SPC)
UK

Structural formula

Graphic representation of the active ingredient's molecular structure

Unique ingredient identifier (UNII)

3DI2E1X18L - CINNARIZINE

CAS registry number

298-57-7 - cinnarizine

SNOMED-CT

395955001 - Cinnarizine (substance)